Beverley J. Hunt
Research Subjects
Beverley J. Hunt has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
George B. Haycock
Dept of Paediatric Nephrology, Guy’s & St Thomas’ Trust, London, UK
3 shared publicationsCorinne H. F. Nevard
Department of Paediatric Nephrology, Guy’s and St. Thomas’ Trust, London, UK
2 shared publicationsFrances M. K. Williams
From the Departments of Haematology and Lupus Research, St Thomas’ Hospital, London, UK
2 shared publicationsGraham R. V. Hughes
From the Departments of Haematology and Lupus Research, St Thomas’ Hospital, London, UK
2 shared publicationsMiha Furlan
Central Haematology Laboratory, University of Bern, Inselspital, Bern, Switzerland
2 shared publicationsAndrew D. Blann
Department of Medicine, City Hospital, Dudley Road, Birmingham B18 7QH, UK
1 shared publication
Latest Publications
- 1 December 2003
- Published by SAGE Publications in Lupus
- Vol. 12 (12) , 929-934
Cerebral haemostasis and antiphospholipid antibodies
One of the major clinical concerns of the antiphospholipid syndrome (APS) is the propensity of antiphospholipid(aPL) antibodiesto cause thrombosis in both the large and small vessels of the brain. In this article, we review the current understandingof haemostasis in cerebral circulation and discuss this in the context of antiphospholipidantibodies. The systemic-defect-local-phenotypeparadox is of particular importance in this discussion. In this paradigm, a systemic defect in thrombosis and haemostasis leads to a localized pattern of thrombotic disease because the regional physiological variations in the several prothromboticand anticoagulantfactors and the defect interact so as to favour thrombosis at a particular site. One possible mechanism of initiation of thrombosis in APS is the activation of endothelialcells by aPL that could occur in the cerebral vessels and provoke thrombosis. We review the evidence from gene knockout mice, other animal models and human postmortem examination studies as to which pro- and antithrombotic mechanisms are effecting haemostasis in the cerebral circulation. We conclude that there are large deficits in the understanding of the regulation of haemostasis in the human brain. As a consequencethere is a lack of knowledgeabout the effect of aPL on cerebral endothelium and thrombosis. Recent developments in gene expression profiling may have an impact on our understandingof endothelialfunctionin the brain. More research is required.
- 1 December 2003
- Published by SAGE Publications in Lupus
- Vol. 12 (12) , 929-934
Cerebral haemostasis and antiphospholipid antibodies
One of the major clinical concerns of the antiphospholipid syndrome (APS) is the propensity of antiphospholipid(aPL) antibodiesto cause thrombosis in both the large and small vessels of the brain. In this article, we review the current understandingof haemostasis in cerebral circulation and discuss this in the context of antiphospholipidantibodies. The systemic-defect-local-phenotypeparadox is of particular importance in this discussion. In this paradigm, a systemic defect in thrombosis and haemostasis leads to a localized pattern of thrombotic disease because the regional physiological variations in the several prothromboticand anticoagulantfactors and the defect interact so as to favour thrombosis at a particular site. One possible mechanism of initiation of thrombosis in APS is the activation of endothelialcells by aPL that could occur in the cerebral vessels and provoke thrombosis. We review the evidence from gene knockout mice, other animal models and human postmortem examination studies as to which pro- and antithrombotic mechanisms are effecting haemostasis in the cerebral circulation. We conclude that there are large deficits in the understanding of the regulation of haemostasis in the human brain. As a consequencethere is a lack of knowledgeabout the effect of aPL on cerebral endothelium and thrombosis. Recent developments in gene expression profiling may have an impact on our understandingof endothelialfunctionin the brain. More research is required.
- 1 October 2003
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 1 (10) , 2131-2133
Is mild normobaric hypoxia a risk factor for venous thromboembolism?
- 1 October 2003
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 1 (10) , 2131-2133
Is mild normobaric hypoxia a risk factor for venous thromboembolism?
- 1 January 2002
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 87 (05) , 918
Is a Nihilistic Attitude to Thrombophilia Screening Justified?
- 1 January 2002
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 87 (05) , 918
Is a Nihilistic Attitude to Thrombophilia Screening Justified?
- 1 January 2002
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 87 (03) , 549-550
Reply to Rebuttal: von Willebrand Factor-cleaving Protease in Childhood Diarrhoea-associated Haemolytic Uraemic Syndrome
- 1 January 2002
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 87 (03) , 549-550
Reply to Rebuttal: von Willebrand Factor-cleaving Protease in Childhood Diarrhoea-associated Haemolytic Uraemic Syndrome
- 1 January 2001
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 85 (06) , 975-978
Von Willebrand Factor-cleaving Protease in Childhood Diarrhoea-associated Haemolytic Uraemic Syndrome
A deficiency of von Willebrand factor (vWF)-cleaving protease, either due to a congenital deficiency or to the presence of a protease inhibitor of vWF-cleaving protease has been associated with thrombotic thrombocytopenic purpura (TTP). We have studied vWF-cleaving protease in diarrhoea-associated haemolytic uraemic syndrome (D+ HUS), which shares clinical features with TTP. 29 children with acute D+ HUS and 13 control children were studied. vWF-cleaving protease activity was normal (range 50-150%) in 39 of 42 plasma samples. Levels of protease activity between 25 and 50% were noted in plasma from two D+ HUS patients. One D+HUS patient, who had clinical features of TTP, had a vWF-cleaving protease inhibitor producing a severe deficiency of vWF-cleaving protease. Thus a deficiency of vWF-cleaving protease appears to be atypical in D+HUS. The detection of a vWF-cleaving protease inhibitor in one patient suggests it may be associated with infection such as E. coli 0157.
- 1 January 2001
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 85 (06) , 975-978
Von Willebrand Factor-cleaving Protease in Childhood Diarrhoea-associated Haemolytic Uraemic Syndrome
A deficiency of von Willebrand factor (vWF)-cleaving protease, either due to a congenital deficiency or to the presence of a protease inhibitor of vWF-cleaving protease has been associated with thrombotic thrombocytopenic purpura (TTP). We have studied vWF-cleaving protease in diarrhoea-associated haemolytic uraemic syndrome (D+ HUS), which shares clinical features with TTP. 29 children with acute D+ HUS and 13 control children were studied. vWF-cleaving protease activity was normal (range 50-150%) in 39 of 42 plasma samples. Levels of protease activity between 25 and 50% were noted in plasma from two D+ HUS patients. One D+HUS patient, who had clinical features of TTP, had a vWF-cleaving protease inhibitor producing a severe deficiency of vWF-cleaving protease. Thus a deficiency of vWF-cleaving protease appears to be atypical in D+HUS. The detection of a vWF-cleaving protease inhibitor in one patient suggests it may be associated with infection such as E. coli 0157.
- 1 May 2000
- Published by Springer Nature in Current Rheumatology Reports
- Vol. 2 (3) , 252-255
Antiphospholipid antibodies and the endothelium
- 1 May 2000
- Published by Springer Nature in Current Rheumatology Reports
- Vol. 2 (3) , 252-255
Antiphospholipid antibodies and the endothelium
- 1 March 2000
- Published by SAGE Publications in Lupus
- Vol. 9 (3) , 189-193
The endothelium in atherogenesis
The focus of this article is an overview of the endothelial changes that initiate and perpetuate the process of atherogenesis. The endothelium can undergo a series of changes which allow it to participate in the inflammatory response; this is known as endothelial cell activation (ECA). The five core changes of ECA are loss of vascular integrity; expression of leucocyte adhesion molecules; change in phenotype from antithrombotic to prothrombotic; cytokine production, and upregulation of HLA molecules. The diverse effects of ECA share a common intracellular control mechanism through the activation of the transcription factors including Nuclear Factor kB. ECA is an initiating step in atherogenesis. Modified low density lipoproteins are probably the major cause of endothelial cell activation in atherogenesis, and become especially so after oxidation, glycation (in diabetes) or incorporation in immune complexes. In antiphospholipid syndrome (APS), antiendothelial cell antibodies have been detected in up to 67% of patients. In vitro studies suggest that aPL causes ECA and thus lead to speculation that aPL by causing ECA may initiate atherogenesis. Further clinical and in vitro studies are required to address these issues.
- 1 March 2000
- Published by SAGE Publications in Lupus
- Vol. 9 (3) , 189-193
The endothelium in atherogenesis
The focus of this article is an overview of the endothelial changes that initiate and perpetuate the process of atherogenesis. The endothelium can undergo a series of changes which allow it to participate in the inflammatory response; this is known as endothelial cell activation (ECA). The five core changes of ECA are loss of vascular integrity; expression of leucocyte adhesion molecules; change in phenotype from antithrombotic to prothrombotic; cytokine production, and upregulation of HLA molecules. The diverse effects of ECA share a common intracellular control mechanism through the activation of the transcription factors including Nuclear Factor kB. ECA is an initiating step in atherogenesis. Modified low density lipoproteins are probably the major cause of endothelial cell activation in atherogenesis, and become especially so after oxidation, glycation (in diabetes) or incorporation in immune complexes. In antiphospholipid syndrome (APS), antiendothelial cell antibodies have been detected in up to 67% of patients. In vitro studies suggest that aPL causes ECA and thus lead to speculation that aPL by causing ECA may initiate atherogenesis. Further clinical and in vitro studies are required to address these issues.
- 1 January 2000
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 84 (11) , 742-746
Systemic Endothelial Cell Markers in Primary Antiphospholipid Syndrome
The pathogenic mechanism underlying the prothrombotic tendency of Hughes’ or antiphospholipid syndrome (APS) has not been elucidated. Numerous procoagulant mechanisms have been tested including platelet activation, monocyte tissue factor (TF) expression and endothelial cell (EC) activation. There is some evidence for the latter from studies on cultured human umbilical vein endothelial cells (HUVEC). Incubation with antiphospholipid antibodies (aPL) induces EC activation in vitro. We investigated whether there was evidence of EC perturbation in vivo using enzyme-linked immunosorbant assays (ELISAs) for soluble markers of EC dysfunction. Serum and plasma were collected from controls and patients with primary APS and ELISAs performed to quantify soluble vascular cell adhesion molecule (sVCAM), soluble intercellular adhesion molecule-1 (sICAM-1), interleukin-6 (IL-6), endothelin-1 (ET-1), von Willebrand factor (vWF) and soluble tissue factor (sTF). In addition, soluble p-selectin (p-selectin) and vascular endothelial growth factor (VEGF) were measured: the former as a marker of platelet activation, the latter as a potential mediator of TF expression. No significant differences in the levels of blood-borne soluble markers were detected between the patient and control groups except for VEGF and sTF, patients having significantly higher levels of VEGF and sTF than controls (p * F. M. K. Williams is an ARC Clinical Research Fellow.
- 1 January 2000
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 84 (11) , 742-746
Systemic Endothelial Cell Markers in Primary Antiphospholipid Syndrome
The pathogenic mechanism underlying the prothrombotic tendency of Hughes’ or antiphospholipid syndrome (APS) has not been elucidated. Numerous procoagulant mechanisms have been tested including platelet activation, monocyte tissue factor (TF) expression and endothelial cell (EC) activation. There is some evidence for the latter from studies on cultured human umbilical vein endothelial cells (HUVEC). Incubation with antiphospholipid antibodies (aPL) induces EC activation in vitro. We investigated whether there was evidence of EC perturbation in vivo using enzyme-linked immunosorbant assays (ELISAs) for soluble markers of EC dysfunction. Serum and plasma were collected from controls and patients with primary APS and ELISAs performed to quantify soluble vascular cell adhesion molecule (sVCAM), soluble intercellular adhesion molecule-1 (sICAM-1), interleukin-6 (IL-6), endothelin-1 (ET-1), von Willebrand factor (vWF) and soluble tissue factor (sTF). In addition, soluble p-selectin (p-selectin) and vascular endothelial growth factor (VEGF) were measured: the former as a marker of platelet activation, the latter as a potential mediator of TF expression. No significant differences in the levels of blood-borne soluble markers were detected between the patient and control groups except for VEGF and sTF, patients having significantly higher levels of VEGF and sTF than controls (p * F. M. K. Williams is an ARC Clinical Research Fellow.
- 31 July 1999
- Vol. 319 (7205) , 320-1
Safer non-cardiac surgery for patients with coronary artery disease. Preoperative aspirin does increase risk of perioperative bleeding.
- 31 July 1999
- Vol. 319 (7205) , 320-1
Safer non-cardiac surgery for patients with coronary artery disease. Preoperative aspirin does increase risk of perioperative bleeding.